{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:08:47Z","timestamp":1784920127998,"version":"3.55.0"},"reference-count":37,"publisher":"Bentham Science Publishers Ltd.","issue":"6","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDR"],"published-print":{"date-parts":[[2019,10,22]]},"abstract":"<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>The epidemic of T2DM is rising across the globe. Systemic inflammation plays a\npivotal role in the pathogenesis and complications of T2DM. Combination of two or more oral hypoglycemic\nagents (OHA) is widely prescribed in patients with T2DM, however many patients have poor\nglycemic control despite receiving combination therapy. The new antidiabetic drugs are relatively\ncostly or many patients have anxiety over the use of injectable insulin. The objective of this observational\nstudy was to investigate the effectiveness and tolerability of hydroxychloroquine (HCQ) in\nT2DM patients uncontrolled on multiple OHA and despite high sugar level not willing to initiate insulin\ntherapy in a real-world clinical setting.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>A prospective, investigator-initiated, observational, single-centred study was conducted\nwhere 250 patients (18-65 years) with T2DM for more than 5 years, with uncontrolled glycemia despite\non a combination of multiple OHA, HbA1c between \u22657% and &lt;10.5%, FPG &gt;130 mg\/dL or PPG &gt;180\nmg\/dL and BMI between &gt;25 and &lt;39 kg\/m2, were prescribed hydroxychloroquine sulphate 400 mg\nonce daily for 48 weeks. Percentage of drugs used at the baseline were as follows: metformin 2000 mg\n(100%), glimepiride 4 mg (100%), pioglitazone 30 mg (100%), sitagliptin 100 mg (100%), canagliflozin\n300 mg (52.4%), empagliflozin 25 mg (22.8%), dapagliflozin 10 mg (17.6%) and voglibose 0.3\nmg (62%). Mean change in HbA1c, blood glucose and hs-CRP at baseline, week 12, 24 and 48 were\nassessed using the paired t-test.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>After 48 weeks of add-on treatment with HCQ, almost all SGLT-2 inhibitors were withdrawn;\nmetformin dose was reduced to 1000 mg, glimepiride reduced to 1 mg and sitagliptin reduced to 50 mg\nOD. Patients continued to have good glycemic control. HbA1c was reduced from 8.83% to 6.44%. Reduction\nin FPG was 40.78% (baseline 177.30 mg\/dL) and PPG was reduced by 58.95% (baseline\n329.86 mg\/dL). Change in mean body weight was -4.66 Kg. The reduction in glycemic parameters and\nmean body weight was significant (p &lt; 0.0001). Hs-CRP was significantly reduced from 2.70\u00b11.98\nmg\/L to 0.71\u00b10.30 mg\/L 9 (p &lt; 0.0001). More reduction in glycemic parameters and body weight was\nobserved among the patients with higher hs-CRP (&gt; 3 mg\/L) as compared to patients with baseline hs-\nCRP \u2264 3 mg\/L. Most common adverse events reported with the drug therapy were GI irritation (3.6%)\nand hypoglycemia (2%). None of the patients required medical assistance for hypoglycemia.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Add-on treatment of HCQ effectively improved glycemic control in T2DM patients uncontrolled\non multiple antidiabetic drugs. By virtue of its antidiabetic and anti-inflammatory properties,\nit may emerge as a valuable therapeutic intervention for the patients with T2DM.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573399815666190425182008","type":"journal-article","created":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T15:17:23Z","timestamp":1556205443000},"page":"510-519","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Real-World Clinical Effectiveness and Tolerability of Hydroxychloroquine 400 Mg in Uncontrolled Type 2 Diabetes Subjects who are not Willing to Initiate Insulin Therapy (HYQ-Real-World Study)"],"prefix":"10.2174","volume":"15","author":[{"given":"Amit","family":"Gupta","sequence":"first","affiliation":[{"name":"G.D. Diabetes Institute, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4066\/AMJ.2013.1979","volume":"7","author":"Kaveeshwar S.A.","year":"2014","unstructured":"Kaveeshwar S.A.; Cornwall J.; The current state of diabetes mellitus in India. Australas Med J 2014,7(1),45-48","journal-title":"Australas Med J"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"546","DOI":"10.4103\/2230-8210.183480","volume":"20","author":"Chawla A.","year":"2016","unstructured":"Chawla A.; Chawla R.; Jaggi S.; Microvasular and macrovascular complications in diabetes mellitus; Distinct or continuum? Indian J Endocrinol Metab 2016,20(4),546-551","journal-title":"Indian J Endocrinol Metab"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1186\/1472-6963-13-442","volume":"13","author":"Wang T-Y.","year":"2013","unstructured":"Wang T-Y.; Eguale T.; Tamblyn R.; Guidelines adherence in the treatment of patients with newly diagnosed type 2 diabetes: A historical cohort comparing the use of metformin in Quebec pre-and post-Canadian Diabetes Association guidelines. BMC Health Serv Res 2013,13,442","journal-title":"BMC Health Serv Res"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1056\/NEJMoa1003795","volume":"363","author":"Zoungas S.","year":"2010","unstructured":"Zoungas S.; Patel A.; Chalmers J.; Severe hypoglycaemia and risks of vascular events and death. N Engl J Med ADVANCE Collaborative Group2010,363,1410-1418","journal-title":"N Engl J Med"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","volume":"32","author":"Nathan D.M.","year":"2009","unstructured":"Nathan D.M.; Buse J.B.; Davidson M.B.; American Diabetes Association. Medical management of hyperglycaemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009,32,193-203","journal-title":"Diabetes Care"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/S0140-6736(08)60762-X","volume":"371","author":"Weng J.","year":"2008","unstructured":"Weng J.; Li Y.; Xu W.; Shi L.; Zhang Q.; Zhu D.; Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: A multicentre randomised parallel-group trial. Lancet 2008,371,1753-1760","journal-title":"Lancet"},{"key":"ref=7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-014260","volume":"7","author":"Syed A.","year":"2017","unstructured":"Syed A.; Mohd Don Z.; Ng C.J.; Using a patient decision aid for insulin initiation in patients with type 2 diabetes: A qualitative analysis of doctor\u2013patient conversations in primary care consultations in Malaysia. BMJ Open 2017,7","journal-title":"BMJ Open"},{"key":"ref=8","first-page":"S64","volume":"40","year":"2017","unstructured":"Pharmacologic Approaches to Glycaemic Treatment. American Diabetes Association SO Diabetes Care 2017,40(Suppl. 1),S64-S74","journal-title":"American Diabetes Association SO Diabetes Care"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"S139","DOI":"10.2337\/dcS13-2035","volume":"36","author":"Raz I.","year":"2013","unstructured":"Raz I.; Guideline Approach to Therapy in Patients with Newly Diagnosed Type 2 Diabetes. Diabetes Care 2013,36(Suppl. 2),S139-S144","journal-title":"Diabetes Care"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jama.298.2.187","volume":"298","author":"Wasko M.C.","year":"2007","unstructured":"Wasko M.C.; Hubert H.B.; Lingala V.B.; Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 2007,298,187-193","journal-title":"JAMA"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0024-3205(98)00568-2","volume":"64","author":"Emami J.","year":"1999","unstructured":"Emami J.; Pasutto F.; Mercer J.R.; Jamali F.; Inhibition of insulin metabolism by hydroxychloroquine and its enantiomers in cytosolic fraction of liver homogenates from healthy and diabetic rats. Life Sci 1999,64,325-335","journal-title":"Life Sci"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"R135","DOI":"10.1186\/ar3868","volume":"14","author":"Mercer E.","year":"2012","unstructured":"Mercer E.; Rekedal L.; Garg R.; Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals. Arthritis Res Ther 2012,14,R135","journal-title":"Arthritis Res Ther"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jama.298.2.187","volume":"298","author":"Wasko M.C.M.","year":"2007","unstructured":"Wasko M.C.M.; Hubert H.B.; Lingala V.B.; Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 2007,298(2),187-193","journal-title":"JAMA"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1001\/jama.2011.878","volume":"305","author":"Solomon D.H.","year":"2011","unstructured":"Solomon D.H.; Massarotti E.; Garg R.; Association between disease modifying anti-rheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 2011,305(24),2525-2531","journal-title":"JAMA"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/RHU.0b013e318214b6b5","volume":"17","author":"Bili A.","year":"2011","unstructured":"Bili A.; Sartorius J.A.; Kirchner H.L.; Hydroxychloroquine use and decreased risk of diabetes in rheumatoid arthritis patients. J Clin Rheumatol 2011,17,115-120","journal-title":"J Clin Rheumatol"},{"key":"ref=16","author":"Chen Y.M.","year":"2015","unstructured":"Chen Y.M.; Lin C.H.; Lan T.H.; Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose dependent manner: a population-based cohort study. Rheumatology (Oxford) Jan 12[Epub ahead of print].2015","journal-title":"Rheumatology (Oxford)"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"678","DOI":"10.7326\/0003-4819-112-9-678","volume":"112","author":"Quatraro A.","year":"1990","unstructured":"Quatraro A.; Consoli G.; Magno M.; Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. Annals of Internal Med 1990,112,678-681","journal-title":"Annals of Internal Med"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0168-8227(01)00325-4","volume":"55","author":"Gerstein H.","year":"2002","unstructured":"Gerstein H.; Thorpe K.; Taylor D.; The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas - a randomized trial. Diabetes Res Clin Pract 2002,55,209-219","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1002\/art.27703","volume":"62","author":"Rekedal L.R.","year":"2010","unstructured":"Rekedal L.R.; Massarotti E.; Garg R.; Changes in Glycated Hemoglobin after Initiation of Hydroxychloroquine or Methotrexate in Diabetic Patients with Rheumatologic Diseases. Arthritis Rheum 2010,62(12),3569-3573","journal-title":"Arthritis Rheum"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1185\/03007995.2014.909393","volume":"30","author":"Pareek A.","year":"2014","unstructured":"Pareek A.; Chandurkar N.; Thomas N.; Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone. Curr Med Res Opin 2014,30(7),1257-1266","journal-title":"Curr Med Res Opin"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/nrendo.2011.183","volume":"8","author":"Chen L.","year":"2012","unstructured":"Chen L.; Magliano D.J.; Zimmet P.Z.; The worldwide epidemiology of type 2 diabetes mellitus \u2013 present and future perspectives. Nat Rev Endocrinol 2012,8,228-236","journal-title":"Nat Rev Endocrinol"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","year":"1998","unstructured":"Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet UK Prospective Diabetes Study (UKPDS) Group1998,352,837-853","journal-title":"Lancet"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","volume":"352","year":"1998","unstructured":"Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet UK Prospective Diabetes Study (UKPDS) Group1998,352,854-865","journal-title":"Lancet"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"771","DOI":"10.4172\/2155-6156.1000771","volume":"8","author":"Jagnani V.K.","year":"2017","unstructured":"Jagnani V.K.; Bhattacharya N.R.; Satpathy S.C.; Effect of hydroxychloroquine on type 2 diabetes mellitus unresponsive to more than two oral antidiabetic agents. J Diabetes Metab 2017,8(10),771","journal-title":"J Diabetes Metab"},{"key":"ref=25","first-page":"2150","volume":"6","author":"Surendra P.S.","year":"2018","unstructured":"Surendra P.S.; Comparative study to evaluate effect of hydroxychloroquine versus sitagliptin as add on therapy in patients with type 2 diabetes inadequately controlled on combination with metformin and gliclazide: a multicentre, observational trial. Sch J App Med Sci 2018,6(5),2150-2156","journal-title":"Sch J App Med Sci"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"409","DOI":"10.18535\/jmscr\/v6i4.6 8","volume":"6","author":"Baidya A","year":"2018","unstructured":"Baidya A; Kumar M; Pathak SK; Study of comparative effect of hydroxychloroquine and vildagliptin on glycaemic efficacy and HbA1c in type 2 diabetes patients who were inadequately controlled with metformin and glimepiride dual therapy. JMSCR 2018,6(4),409-15","journal-title":"JMSCR"},{"key":"ref=27","first-page":"283","volume":"7","author":"Baidya A","year":"20118","unstructured":"Baidya A; Chakravarti HN; Saraogi RK; Efficacy of maximum and optimum doses of hydroxychloroquine added to patients with poorly controlled type 2 diabetes on stable insulin therapy along with glimepiride and metformin: association of high sensitive c-reactive protein (Hs-CRP) and glycosylated haemoglobin (HbA1c). Endocrinol Metab Syndr 20118,7,283","journal-title":"Endocrinol Metab Syndr"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.29328\/journal.acem.1001009","volume":"2","author":"Ranjan P.","year":"2018","unstructured":"Ranjan P.; Ahsan S.; Bhushan R.; Comparison of effi cacy and safety of hydroxychloroquine and teneligliptin in type 2 diabetes patients who are inadequately controlled with glimepiride, metformin and insulin therapy: A randomized controlled trial with parallel group design. Ann Clin Endocrinol Metabol 2018,2,30-40","journal-title":"Ann Clin Endocrinol Metabol"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.18203\/2319-2003.ijbcp20183930","volume":"7","author":"Kumar V.","year":"2018","unstructured":"Kumar V.; Singh M.P.; Singh A.P.; Pandey M.S.; Kumar S.; Kumar S.; Efficacy and safety of hydroxychloroquine when added to stable insulin therapy in combination with metformin and glimepiride in patients with type 2 diabetes compare to sitagliptin. Int J Basic Clin Pharmacol 2018,7,1959-1964","journal-title":"Int J Basic Clin Pharmacol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"209","DOI":"10.5603\/DK.2018.0025","volume":"7","author":"Singh U.P.","year":"2018","unstructured":"Singh U.P.; Baidya A.; Singla M.; Efficacy and safety of substituting teneligliptin with hydroxychloroquine in inadequately controlled type 2 diabetes subjects with combination therapy of teneligliptin, metformin and glimepiride with or without other antidiabetic therapy: The TENE-HYQ SHIFT Study. Clinical Diabetology 2018,7(5),209-214","journal-title":"Clinical Diabetology"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1177\/0145721708317869","volume":"34","author":"Larkin M.E.","year":"2008","unstructured":"Larkin M.E.; Capasso V.A.; Chen C.L.; Measuring psychological insulin resistance: Barriers to insulin use. Diabetes Educ 2008,34(3),511-517","journal-title":"Diabetes Educ"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.2337\/diacare.28.11.2673","volume":"28","author":"Peyrot M.","year":"2005","unstructured":"Peyrot M.; Rubin R.R.; Lauritzen T.; Resis tance to insulin therapy among patients and providers results of the cross-national diabetes attitudes, wishes, and needs (DAWN) study. Diabetes Care 2005,28(11),2673-2679","journal-title":"Diabetes Care"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.arr.2013.05.007","volume":"12","author":"Finelli C.","year":"2013","unstructured":"Finelli C.; Sommella L.; Gioia S.; La Sala N.; Tarantino G.; Should visceral fat be reduced to increase longevity? Ageing Res Rev 2013,12(4),996-1004","journal-title":"Ageing Res Rev"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"3222","DOI":"10.1158\/1078-0432.CCR-13-3227","volume":"20","author":"Katherine C.","year":"2014","unstructured":"Katherine C.; 1 Anni W, David RS, Pamela AGC, Cruz MI, Alan Z, Robert C. Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer. Clin Cancer Res Erratum in: Clin Cancer Res. 2016 Jun 1; 22 (11): 2825.2014,20(12),3222-3232","journal-title":"Clin Cancer Res"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.acthis.2016.06.002","volume":"118","author":"Abdel-Hamid A.A.M.","year":"2016","unstructured":"Abdel-Hamid A.A.M.; Firgany A.E.L.; Favorable outcomes of hydroxychloroquine in insulin resistance may be accomplished by adjustment of the endothelial dysfunction as well as the skewed balance of adipokines. Acta Histochem 2016,118(6),560-573","journal-title":"Acta Histochem"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"219","DOI":"10.15171\/bi.2017.26","volume":"7","author":"Rezabakhsh A.","year":"2017","unstructured":"Rezabakhsh A.; Montazersaheb S.; Nabat E.; Effect of hydroxychloroquine on oxidative\/nitrosative status and angiogenesis in endothelial cells under high glucose condition. Bioimpacts 2017,7(4),219-226","journal-title":"Bioimpacts"},{"key":"ref=37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210459","volume":"14","author":"Lillegraven S.","year":"2019","unstructured":"Lillegraven S.; Greenberg J.D.; Reed G.W.; Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis. PLoS One 2019,14(1)","journal-title":"PLoS One"}],"container-title":["Current Diabetes Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/171853","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T15:04:39Z","timestamp":1575903879000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/171853\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,22]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,10,22]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573399815666190425182008","relation":{},"ISSN":["1573-3998"],"issn-type":[{"value":"1573-3998","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10,22]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-02-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}